Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms

BMC Neurology

Table 1 Characteristics of the patients included in the analysis

	Controls	MSA			PD	VaP	PD/VaPD	p value^a
N	25	MSA-P	MSA-C	MSA-P/C	44	9	7
		11	2	1	44	9	7
		14
Age (at inclusion)	64.5 ± 10.3	61.1 ± 8.0			57.9 ± 9.9	69.5 ± 9.0	70.2 ± 5.1	0.003
Sex (male/female)	11/14	9/5			28/16	7/2	6/1	0.004
Disease duration since first symptoms (months)	N.A.	38.9 ± 38.3			42.0 ± 34.3	25.5 ± 16.11	41.0 ± 19.8	0.556
Disease Severity (baseline)
HY score	N.A.	2.7 ± 0.8 (14)			2.0 ± 0.6 (43)	2.9 ± 0.7 (9)	2.6 ± 0.9 (7)	0.001
UPDRS-III score	N.A.	30.3 ± 10.0 (14)			28.2 ± 13.8 (42)	33.1 ± 11.3 (9)	40.1 ± 16.8 (7)	0.203
ICARS score	N.A.	10.9 ± 11.5 (11)			2.8 ± 3.4 (39)	10.7 ± 5.1 (7)	8.8 ± 6.1 (6)	0.000
MMSE score	N.A.	27.9 ± 2.7 (13)			28.2 ± 2.1 (44)	26.7 ± 2.9 (8)	26.4 ± 1.5 (7)	0.030
Disease Severity (3 years follow-up)
HY score	N.A.	4.0 ± 1.1 (10)			2.3 ± 0.8 (41)	4.2 ± 1.0 (6)	2.8 ± 0.9 (5)	0.000
UPDRS-III score	N.A.	33.8 ± 6.8 (5)			29.9 ± 15.1 (39)	44.7 ± 9.3 (4)	39.2 ± 20.6 (5)	0.109
ICARS score	N.A.	16.0 ± 17.9 (5)			3.5 ± 3.2 (35)	20.0 ± 5.7 (4)	5.0 ± 2.5 (5)	0.001
MMSE score	N.A.	27.4 ± 1.1 (5)			27.9 ± 2.9 (34)	27.0 ± 4.1 (4)	24.8 ± 5.7 (5)	0.189
Survival after 12 years (dead/alive)	N.A.	13/1			11/33	9/0	4/3

Data are represented as mean ± SD (N). p value was considered significant when < 0.05, MSA multiple system atrophy, PD Parkinson’s disease, VaP vascular parkinsonism, PD/VaP PD with overlapping VaP, MSA-P multiple system atrophy parkinsonian type, MSA-C multiple system atrophy cerebellar type, MSA-P/C multiple system atrophy mixed parkinsonian and cerebellar, N.A not applicable, HY Hoehn and Yahr, UPDRS-III Unified Parkinson’s Disease Rating Scale part III (motor score), ICARS International Cooperative Ataxia Rating Scale, MMSE Mini-Mental State Examination. ^aKruskal-Wallis test with Bonferroni correction and Chi-square for sex differences

ISSN: 1471-2377